Compare MRCY & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | TVTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.3B |
| IPO Year | 1997 | 2013 |
| Metric | MRCY | TVTX |
|---|---|---|
| Price | $80.76 | $66.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $80.00 | $40.62 |
| AVG Volume (30 Days) | 774.5K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.08 | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $983,622,000.00 | N/A |
| Revenue This Year | $6.59 | $44.76 |
| Revenue Next Year | $9.56 | $35.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $65.04 | $22.06 |
| 52 Week High | $128.45 | $68.03 |
| Indicator | MRCY | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 59.71 |
| Support Level | $71.60 | $53.76 |
| Resistance Level | $88.06 | N/A |
| Average True Range (ATR) | 3.99 | 2.02 |
| MACD | -0.96 | -0.31 |
| Stochastic Oscillator | 4.25 | 59.79 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.